HRP20161069T1 - Molekule antitijela koje vezuju il-17a i il-17f - Google Patents

Molekule antitijela koje vezuju il-17a i il-17f Download PDF

Info

Publication number
HRP20161069T1
HRP20161069T1 HRP20161069TT HRP20161069T HRP20161069T1 HR P20161069 T1 HRP20161069 T1 HR P20161069T1 HR P20161069T T HRP20161069T T HR P20161069TT HR P20161069 T HRP20161069 T HR P20161069T HR P20161069 T1 HRP20161069 T1 HR P20161069T1
Authority
HR
Croatia
Prior art keywords
antibody
seq
disease
light chain
antibody according
Prior art date
Application number
HRP20161069TT
Other languages
English (en)
Inventor
Ralph Adams
Andrew George Popplewell
Stephen Edward Rapecki
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of HRP20161069T1 publication Critical patent/HRP20161069T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)

Claims (17)

1. Neutralizirajuće antitijelo koje vezuje humani IL-17A i humani IL-17F, obuhvaćajući teški lanac i laki lanac, naznačeno time da se teški lanac varijabilnog domena obuhvaćajući sekvencu danu u SEQ ID NO:9 i laki lanac varijabilnog domena obuhvaćajući sekvencu danu u SEQ ID NO:7 ili sekvencu najmanje 95% tome identičnu i pri čemu antitijelo ima afinitet prema IL-17A bolji od 20pM i afinitet prema IL-17F bolji od 2nM.
2. Neutralizirajuće antitijelo prema patentnom zahtjevu 1, naznačeno time da ima teški lanac koji obuhvaća sekvencu danu u SEQ ID NO꞉9 i laki lanac obuhvaćajući sekvencu danu u SEQ ID NO:7.
3. Neutralizirajuće antitijelo prema patentnom zahtjevu 2, koje vezuje humani IL-17A i humani IL-17F, naznačeno time da ima teški lanac koji obuhvaća sekvencu danu u SEQ ID NO:15 i laki lanac koji obuhvaća sekvencu danu u SEQ ID NO:11.
4. Neutralizirajuće antitijelo prema bilo kojem od patentnih zahtjeva od 1 do 3, naznačeno time da je antitijelo cijelo antitijelo ili funkcionalno aktivni fragment ili njegov derivat.
5. Neutralizirajuće antitijelo prema patentnom zahtjevu 4, naznačeno time da je fragment antitijela Fab, Fab', F(ab')2, scFv ili epitopska veza fragmenta iste.
6. Neutralizirajuće antitijelo prema patentnom zahtjevu 4 ili patentnom zahtjevu 5, naznačeno time da je antitijelo ili njegov fragment CDR-presađeno antitijelo.
7. Antitijelo prema bilo kom od patentnih zahtjeva od 1 do 6, naznačeno time da je antitijelo ili njegov fragment istog sjedinjen sa jednim ili više efektor molekula.
8. Izolirana DNK sekvenca koja kodira teški i laki lanac antitijela prema bilo kojem od patentnih zahtjeva od 1 do 6.
9. Kloniranje ili vektor ekspresije koji sadrži jednu ili više DNK sekvenci prema patentnom zahtjevu 8.
10. Vektor prema patentnom zahtjevu 9, naznačen time da vektor obuhvaća sekvence date u SEQ ID NO:14 i SEQ ID NO:18.
11. Stanica domaćina za ekspresiju antitijela prema bilo kojem od patentnih zahtjeva od 1 do 6, obuhvaćajući: i) DNK sekvencu koja kodira teški lanac navedenog antitijela, i ii) DNK sekvencu koja kodira laki lanac navedenog antitijela naznačen time da se DNK sekvence daju u jednom ili više kloniranja ili vektora ekspresije.
12. Stanica domaćina prema patentnom zahtjevu 11, naznačena time da obuhvaća jedno ili više kloniranja ili vektora ekspresije prema patentnom zahtjevu 9 ili patentnom zahtjevu 10.
13. Proces za proizvodnju antitijela prema bilo kojem od patentnih zahtjeva od 1 do 6, naznačen time da obuhvaća uzgajanje kulture stanica domaćina iz patentnog zahtjeva 11 i izoliranog antitijela.
14. Farmaceutski sastav koji sadrži obuhvaćajući antitijelo prema bilo kom od patentnih zahtjeva od 1 do 6, naznačen time da je u kombinaciji sa jednim ili više farmaceutski prihvatljivih ekscipijensa, razrjeđivača ili nosača.
15. Farmaceutski sastav prema patentnom zahtjevu 14, naznačen time da dodatno sadrži druge aktivne sastojke.
16. Antitijelo prema bilo kojem od patentnih zahtjeva od 1 do 6 ili farmaceutski sastav prema patentnom zahtjevu 14 ili patentnom zahtjevu 15, naznačeni time da su za upotrebu u terapiji.
17. Antitijelo prema bilo kojem od patentnih zahtjeva od 1 do 6 ili farmaceutski sastav prema zahtjevu 14 ili zahtjevu 15, naznačeni time da su za upotrebu u liječenju ili profilaksi patoloških poremećaja posredovano od IL-17A i/ili IL-17F, ili je povezano sa povećanim nivoom IL-17A i/ili IL-17F, pri čemu je patološki poremećaj izabran iz grupe koja se sastoji od infekcija (virusne, bakterijske, gljivične i parazitske), endotoksičkog šoka vezanog za infekcije, artritisa, reumatoidnog artritisa, astme, upalne bolesti karlice, Alzhemierove bolesti, Kronove bolesti, Peyronijeve bolesti, celijaklije, bolesti žučnog mjehura, Pilonidal bolesti, upale trbušne maramice, psorijaze, vaskulitisa, kirurške adhezije, moždanog udara, dijabetesa Tip I, lajmskog artritisa, meningoencefalitisa, imuno posredovanog zapaljivog poremećaja centralnog i perifernog nervnog sistema kao što je multipla skleroza i Guillain-Barr sindrom, druge autoimune bolesti , pankreatitis, traume (operacije), bolesti graft-versus-domaćina, odbacivanja pri transplantaciji, raka (oba, solidna tumora kao što su melanom, hepatoblastom, sarkom, karcinom skvamoznih stanica, rak tranzicijskih stanica, rak jajnika i hematološke malignosti, naročito u akutno mijelidne leukemije, hroničnoj mijeloidne leukemije, raka želuca i raka debelog crijeva), bolesti srca uključujući ishemijske bolesti kao što su infarkt miokarda kao i arteroskleroze, intravaskularna koagulacija, koštana respsorpcija, osteoporoza, paradentoza i hipoklorhidija.
HRP20161069TT 2006-10-18 2007-10-18 Molekule antitijela koje vezuju il-17a i il-17f HRP20161069T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0620729.4A GB0620729D0 (en) 2006-10-18 2006-10-18 Biological products
EP07824232.8A EP2076539B1 (en) 2006-10-18 2007-10-18 Antibody molecules which bind il-17a and il-17f
PCT/GB2007/003983 WO2008047134A2 (en) 2006-10-18 2007-10-18 Antibody molecules which bind il-17a and il-17f

Publications (1)

Publication Number Publication Date
HRP20161069T1 true HRP20161069T1 (hr) 2016-10-21

Family

ID=37507977

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20161069TT HRP20161069T1 (hr) 2006-10-18 2007-10-18 Molekule antitijela koje vezuju il-17a i il-17f
HRP20190932TT HRP20190932T1 (hr) 2006-10-18 2019-05-21 Molekule protutijela koje se vežu na il-17a i il-17f

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20190932TT HRP20190932T1 (hr) 2006-10-18 2019-05-21 Molekule protutijela koje se vežu na il-17a i il-17f

Country Status (27)

Country Link
US (6) US8303953B2 (hr)
EP (3) EP3524623A1 (hr)
JP (4) JP2010506580A (hr)
KR (1) KR20090078355A (hr)
CN (1) CN101589061B (hr)
AU (1) AU2007311689B2 (hr)
BR (1) BRPI0717768B8 (hr)
CA (1) CA2666458C (hr)
CO (1) CO6180467A2 (hr)
CY (2) CY1117963T1 (hr)
DK (2) DK2076539T3 (hr)
EA (1) EA029953B1 (hr)
ES (2) ES2729064T3 (hr)
GB (1) GB0620729D0 (hr)
HR (2) HRP20161069T1 (hr)
HU (2) HUE043667T2 (hr)
IL (1) IL198061B (hr)
LT (1) LT2514764T (hr)
MX (1) MX2009003973A (hr)
PL (2) PL2076539T3 (hr)
PT (2) PT2076539T (hr)
RS (1) RS55031B1 (hr)
SG (1) SG175652A1 (hr)
SI (2) SI2514764T1 (hr)
TR (1) TR201907599T4 (hr)
WO (1) WO2008047134A2 (hr)
ZA (1) ZA200902460B (hr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX341074B (es) 2003-07-08 2016-08-05 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
EP1996622A2 (en) 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
CN101689963B (zh) 2007-04-30 2013-04-03 交互数字技术公司 Mimo无线通信系统中的反馈信令差错检测和校验
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
NZ588674A (en) * 2008-05-05 2013-02-22 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
CA2739971A1 (en) * 2008-10-07 2010-04-15 Novimmune S.A. Il-17-mediated transfection methods
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
SG175276A1 (en) 2009-05-05 2011-11-28 Novimmune Sa Anti-il-17f antibodies and methods of use thereof
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
AU2012206431B2 (en) 2011-01-14 2015-04-30 UCB Biopharma SRL Antibody molecules which bind IL-17A and IL-17F
US9345742B2 (en) 2011-02-08 2016-05-24 Merck Patent Gmbh Aminostatin derivatives for the treatment of arthrosis
WO2012125680A1 (en) * 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
US20140105855A1 (en) * 2011-04-06 2014-04-17 Kenan Christopher Garcia Structural based design of il-17 dominant negative mutants
UA117218C2 (uk) * 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9969813B2 (en) 2012-05-10 2018-05-15 Bioatla, Llc Multi-specific monoclonal antibodies
DK2858670T3 (en) * 2012-06-12 2018-10-22 Orega Biotech Antagonists of IL-17 isoforms and their applications
CN104231080B (zh) * 2013-03-15 2019-07-02 中国医学科学院药物研究所 全人源抗人白介素17a单链抗体
GB201310544D0 (en) 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
PL3072905T3 (pl) * 2013-11-18 2021-03-08 Shanghai Hengrui Pharmaceutical Co., Ltd. Środek wiążący il-17a i jego zastosowania
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
EP3212665A2 (en) * 2014-10-31 2017-09-06 F. Hoffmann-La Roche AG Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP2018506275A (ja) * 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
CN108251431B (zh) 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
CN108350068A (zh) 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
TN2019000082A1 (en) 2016-09-14 2020-07-15 Beijing hanmi pharm co ltd Antibody specifically binding to il-17a and functional fragment thereof
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
CN112513081A (zh) 2018-06-14 2021-03-16 生物蛋白有限公司 多重特异性抗体构建体
GB201919061D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
KR20230025890A (ko) 2020-06-23 2023-02-23 노파르티스 아게 인터루킨-17(il-17) 길항제를 이용한 갑상선 안병증 및 그레이브스 안와병증의 치료 방법
CN112390890B (zh) * 2020-11-06 2022-06-24 江苏荃信生物医药股份有限公司 一种定量检测血清中抗人白介素17单克隆抗体含量的酶联免疫分析方法
IT202200016722A1 (it) * 2022-08-04 2024-02-04 Paolo Grieco Nuovo peptide derivato da interleuchina-17A (IL-17A) e anticorpo neutralizzante (Ab17-IPL-1)
EP4393948A1 (en) * 2022-12-28 2024-07-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic vhh antibodies cross-neutralizing the il-17a and il-17f homodimers as well as the il-17af heterodimer
CN118681005A (zh) * 2023-03-23 2024-09-24 上海惠盾因泰生物科技有限公司 一种二价il-17治疗性疫苗及其制备方法和应用
WO2024263945A2 (en) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Il-17 antibody compositions and methods of use
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
BR8907515A (pt) 1988-06-28 1991-05-28 Du Pont Formulacoes de pesticidas em comprimidos
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP1471142B1 (en) 1991-04-10 2008-11-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
WO2004016377A2 (en) 2002-08-16 2004-02-26 Allied Machine & Engineering Corp. Drilling tool and method for producing port seals
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
JP2007536898A (ja) 2003-07-01 2007-12-20 セルテック アール アンド ディ リミテッド 修飾抗体Ｆａｂフラグメント
MX341074B (es) * 2003-07-08 2016-08-05 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
JP4833850B2 (ja) 2003-11-21 2011-12-07 ユセベ ファルマ ソシエテ アノニム Ｉｌ−１７活性阻害による多発性硬化症を治療するための方法
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7910540B2 (en) * 2004-06-10 2011-03-22 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US20080181888A1 (en) * 2004-12-31 2008-07-31 Ambrose Christine M Polypeptides That Bind Br3 and Uses Thereof
TW200641353A (en) * 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
DK1963368T6 (da) 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
EP1996622A2 (en) * 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
US7790163B2 (en) * 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
AU2007284782B2 (en) 2006-08-11 2012-11-15 Merck Sharp & Dohme Corp. Antibodies to IL-17A
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
AU2012206431B2 (en) * 2011-01-14 2015-04-30 UCB Biopharma SRL Antibody molecules which bind IL-17A and IL-17F

Also Published As

Publication number Publication date
PL2514764T3 (pl) 2019-08-30
BRPI0717768B1 (pt) 2021-01-05
AU2007311689A1 (en) 2008-04-24
SI2514764T1 (sl) 2019-07-31
LT2514764T (lt) 2019-06-10
SG175652A1 (en) 2011-11-28
RS55031B1 (sr) 2016-11-30
US10308723B2 (en) 2019-06-04
US20140186355A1 (en) 2014-07-03
TR201907599T4 (tr) 2019-06-21
HUE043667T2 (hu) 2019-08-28
JP2014050391A (ja) 2014-03-20
CN101589061A (zh) 2009-11-25
SI2076539T1 (sl) 2016-09-30
JP2015227342A (ja) 2015-12-17
BRPI0717768B8 (pt) 2021-05-25
JP2010506580A (ja) 2010-03-04
EA200900492A1 (ru) 2009-10-30
EP2514764B1 (en) 2019-03-06
EP2076539B1 (en) 2016-06-08
JP6329516B2 (ja) 2018-05-23
CY1121672T1 (el) 2020-07-31
MX2009003973A (es) 2009-04-28
KR20090078355A (ko) 2009-07-17
CY1117963T1 (el) 2017-05-17
US20170306052A1 (en) 2017-10-26
ES2729064T3 (es) 2019-10-30
EA029953B1 (ru) 2018-06-29
GB0620729D0 (en) 2006-11-29
US20150322147A1 (en) 2015-11-12
WO2008047134A3 (en) 2008-06-12
CN101589061B (zh) 2014-09-17
EP2514764A2 (en) 2012-10-24
US20140044732A1 (en) 2014-02-13
DK2076539T3 (da) 2016-08-15
PL2076539T3 (pl) 2016-12-30
US20100266609A1 (en) 2010-10-21
EP2514764A3 (en) 2013-02-20
WO2008047134A2 (en) 2008-04-24
CA2666458C (en) 2018-06-19
US8617847B2 (en) 2013-12-31
US8303953B2 (en) 2012-11-06
PT2514764T (pt) 2019-06-12
PT2076539T (pt) 2016-09-02
ES2588596T3 (es) 2016-11-03
DK2514764T3 (da) 2019-06-03
AU2007311689B2 (en) 2013-05-16
EP2076539A2 (en) 2009-07-08
IL198061A0 (en) 2011-08-01
JP5856121B2 (ja) 2016-02-09
IL198061B (en) 2018-10-31
US20130102030A1 (en) 2013-04-25
ZA200902460B (en) 2010-07-28
EP3524623A1 (en) 2019-08-14
JP2017169569A (ja) 2017-09-28
HRP20190932T1 (hr) 2019-07-26
BRPI0717768A2 (pt) 2013-11-05
CO6180467A2 (es) 2010-07-19
US9890219B2 (en) 2018-02-13
CA2666458A1 (en) 2008-04-24
HUE029448T2 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
HRP20161069T1 (hr) Molekule antitijela koje vezuju il-17a i il-17f
JP2015227342A5 (hr)
HRP20171034T1 (hr) Antitijelo koje veže il-17a i il-17f
JP2020505386A5 (hr)
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
SI2481753T1 (en) Anti-IL-17 antibodies
JP2010500876A5 (hr)
JP2019519199A5 (hr)
RU2009118621A (ru) Агонистические антитела против notch3 и их применение для лечения ntch3-ассоциированных заболеваний
CL2010001544A1 (es) Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma.
HRP20240495T1 (hr) Anti-garp antitijelo
JP2015508280A5 (hr)
JP2013539369A5 (hr)
JP2016520595A5 (hr)
CN107922499A (zh) 抗EphA4抗体
CN111378037B (zh) 一种抗hIL-33人源化单抗及其应用
HRP20221142T1 (hr) Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću
JP2019505565A5 (hr)
WO2020115115A1 (en) Multispecific antigen-binding molecules
EP3154564B1 (en) New polypeptide
KR20150134319A (ko) 인간화 항 hmgb1 항체 또는 그의 항원 결합성 단편
TW200630381A (en) Tumor endothelial marker-1 (TEM1) binding antibodies and uses thereof
RU2380377C2 (ru) Nogo-A-СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
IL315960A (en) Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
JP2019518473A5 (hr)